<!doctype html>
<html lang="en">
<head>
    <!-- Global site tag (gtag.js) - Google Analytics -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=G-VVR97X6L2R"></script>
    <script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'G-VVR97X6L2R');
    </script>
    
    <title>Clear Your View | Data</title>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">

    <!-- Goole fonts -->
    <!-- <link rel="preconnect" href="https://fonts.gstatic.com">  -->
    <link href="https://fonts.googleapis.com/css2?family=Poppins:wght@500;600;900&family=Roboto:wght@300;400;500;700&display=swap" rel="stylesheet">

    <!-- Material icons -->
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons"
      rel="stylesheet">

    <!-- CSS -->
    <link rel="stylesheet" href="assets/css/theme.css">

    <!-- Favicon -->
    <link rel="icon" href="assets/img/icon.png" type="image/png">

    <!-- JS -->
    <script src="assets/js/theme.js" defer></script>
    <script src="https://code.jquery.com/jquery-3.5.1.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js"></script>
    <script src="https://unpkg.com/@popperjs/core@2"></script>
    <script src="https://www.google.com/recaptcha/api.js" async defer></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/animejs/3.2.1/anime.min.js" integrity="sha512-z4OUqw38qNLpn1libAN9BsoDx6nbNFio5lA6CuTp9NlK83b89hgyCVq+N5FdBJptINztxn1Z3SaKSKUS5UP60Q==" crossorigin="anonymous"></script>


</head>

<body>

<header class="site-header fixed-top ">
    <a href="#content" class="sr-only sr-only-focusable">Skip to main content</a>
    <div class="col-12">

        <!-- Navbar -->
        <nav class="navbar main-nav navbar-expand-lg navbar-light" aria-label="Main navigation">

            <a href="/" class="navbar-brand d-inline-flex">
                <img src="assets/img/logo.svg" alt="Clear Your View">
            </a>

            <button class="navbar-toggler hamburger hamburger--spin" type="button" data-toggle="collapse" data-target="#navbarContent" aria-controls="navbarContent" aria-expanded="false" aria-label="Toggle navigation">

                <span class="hamburger-box">
                    <span class="hamburger-inner"></span>
                </span>

            </button>
  

            <div class="collapse navbar-collapse text-uppercase" id="navbarContent">
                <ul class="navbar-nav ml-auto">
                    
                    <li class="nav-item">
                        <a href="lung.html" class="nav-link">Lung Cancer</a>
                    </li>

                    <li class="nav-item">
                        <a href="colo.html" class="nav-link">Colorectal Cancer</a>
                    </li>

                    <li class="nav-item">
                        <a href="data.html" class="nav-link active">Data</a>
                    </li>

                    <li class="nav-item">
                        <a href="resources.html" class="nav-link">Resources</a>
                    </li>

                    <li class="nav-item">
                        <a href="news.html" class="nav-link">News & Media</a>
                    </li>

                    <li class="nav-item">
                        <a href="thank-you.html" class="btn btn-primary btn-sm">Commit to Test</a>
                    </li>


                </ul>
            </div>
        </nav>
    </div>
</header>



    <main id="content">

        <div class="diagonal-hero bg-red text-dark">
            <div class="row no-gutters">
                <div class="col-lg-5">
					<picture>
                        <source srcset="assets/img/shared/hero-desktop-tall.svg"
                            media="(min-width: 992px)">
						<source srcset="assets/img/shared/hero-tablet.svg"
                            media="(min-width: 768px)">                            
                        <source srcset="assets/img/shared/hero-mobile.svg"
                            media="(min-width: 0px)">
                        <img src="assets/img/shared/hero-desktop-tall.svg" alt="" class="w-100" />
                    </picture>
                </div>
                <div class="col-lg-7 row no-gutters align-items-lg-center px-3 px-lg-4 px-xl-5  py-5 py-lg-0">
                	<div class="diagonal-hero-text">
	                    <h2 class="font-weight-semibold">Data</h2>
	                    <p class="lead-2 font-heading font-weight-normal mt-4 mb-0">Low adoption of recommended biomarker testing in NSCLC and CRC and inappropriate treatment selection for patients with these cancers are increasingly highlighted in prominent&nbsp;publications</p>
                	</div>
                </div>
            </div>
        </div>





        <div class="container bg-gray050 my-6">





            <div class="row">

                <div class="col-lg-6">
                    <div class="data-card">
                        <div class="data-card-header">
                            <h4 class="font-sans-serif mb-1">Gastroenterology Report</h4>
                            <p>June 3, 2020</p>
                        </div>
                        <div class="data-card-body">
                            <p class="lead-2">Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance</p>
                            <p class="font-weight-light mb-4">Cetuximab and panitumumab, as the highly effective antibodies targeting EGFR, have clinical activity in the patients with metastatic CRC&hellip;</p>

                            <a href="https://academic.oup.com/gastro/article/8/3/179/5861161" class="text-red text-uppercase" target="_blank">Read more</a>
                        </div>
                    </div>
                </div>

                <div class="col-lg-6 mt-4 mt-lg-0">
                    <div class="data-card">
                        <div class="data-card-header">
                            <h4 class="font-sans-serif mb-1">JCO Precision Oncology</h4>
                            <p>December 6, 2019</p>
                        </div>
                        <div class="data-card-body">
                            <p class="lead-2">Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer</p>
                            <p class="font-weight-light mb-4">Genomic testing is recognized in national guidelines as essential to guide appropriate therapy selection in metastatic colorectal cancer&hellip;</p>

                            <a href="https://ascopubs.org/doi/full/10.1200/PO.19.00274" class="text-red text-uppercase" target="_blank">Read more</a>
                        </div>
                    </div>
                </div>

            </div>




            <div class="row mt-4">

                <div class="col-lg-6">
                    <div class="data-card">
                        <div class="data-card-header">
                            <h4 class="font-sans-serif mb-1">NEJM</h4>
                            <p>October 24, 2019</p>
                        </div>
                        <div class="data-card-body">
                            <p class="lead-2">Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer</p>
                            <p class="font-weight-light mb-4">A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival in patients with metastatic colorectal cancer with the BRAF V600E mutation&hellip;</p>

                            <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1908075" class="text-red text-uppercase" target="_blank">Read more</a>
                        </div>
                    </div>
                </div>

                <div class="col-lg-6 mt-4 mt-lg-0">
                    <div class="data-card">
                        <div class="data-card-header">
                            <h4 class="font-sans-serif mb-1">World J Gastrointest Oncol</h4>
                            <p>April 15, 2019</p>
                        </div>
                        <div class="data-card-body">
                            <p class="lead-2">Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas</p>
                            <p class="font-weight-light mb-4">While the role of HER2 as a prognostic biomarker in CRC remains uncertain, its relevance as a therapeutic target has been established&hellip;</p>

                            <a href="https://www.wjgnet.com/1948-5204/full/v11/i4/335.htm" class="text-red text-uppercase" target="_blank">Read more</a>
                        </div>
                    </div>
                </div>

            </div>            





            <div class="row mt-4">

                <div class="col-lg-6">
                    <div class="data-card">
                        <div class="data-card-header">
                            <h4 class="font-sans-serif mb-1">Clin Cancer Res</h4>
                            <p>December 15, 2015</p>
                        </div>
                        <div class="data-card-body">
                            <p class="lead-2">Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer</p>
                            <p class="font-weight-light mb-4">We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis&hellip;</p>

                            <a href="#" class="text-red text-uppercase" target="_blank">Read more</a>
                        </div>
                    </div>
                </div>

                <div class="col-lg-6 mt-4 mt-lg-0">
                    <div class="data-card">
                        <div class="data-card-header">
                            <h4 class="font-sans-serif mb-1">Journal of Clinical Oncology</h4>
                            <p>May 25, 2020</p>
                        </div>
                        <div class="data-card-body">
                            <p class="lead-2">A retrospective three-year analysis using real-world data on uptake of broad-based NextGen sequencing panels in community oncology practices</p>
                            <p class="font-weight-light mb-4">There are over 100 FDA approved targeted therapies across 15 cancer types, offering improved outcomes over existing therapies. However, many of these require genetic testing, for example, advanced non-small cell&hellip;</p>

                            <a href="https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e13668" class="text-red text-uppercase" target="_blank">Read more</a>
                        </div>
                    </div>
                </div>

            </div>            




            <div class="row mt-4">

                <div class="col-lg-6">
                    <div class="data-card">
                        <div class="data-card-header">
                            <h4 class="font-sans-serif mb-1">National Comprehensive Cancer Network</h4>
                            <p>February 11, 2020</p>
                        </div>
                        <div class="data-card-body">
                            <p class="lead-2">NCCN Guidelines Version 3</p>
                            <p class="font-weight-light mb-4">The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are comprised of recommendations for the prevention, diagnosis, and management of malignancies across the continuum of care. The NCCN Guidelines&reg; currently&hellip;</p>

                            <a href="https://clearyourview.org/wp-content/uploads/2020/04/nscl.pdf" class="text-red text-uppercase" target="_blank">Read more</a>
                        </div>
                    </div>
                </div>

                <div class="col-lg-6 mt-4 mt-lg-0">
                    <div class="data-card">
                        <div class="data-card-header">
                            <h4 class="font-sans-serif mb-1">Annals of Oncology</h4>
                            <p>May 1, 2019</p>
                        </div>
                        <div class="data-card-body">
                            <p class="lead-2">Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib</p>
                            <p class="font-weight-light mb-4">Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). Now that PD-(L)1 inhibitors are&hellip;</p>

                            <a href="https://www.annalsofoncology.org/article/S0923-7534(19)31165-2/abstract" class="text-red text-uppercase" target="_blank">Read more</a>
                        </div>
                    </div>
                </div>

            </div>            




            <div class="row mt-4">

                <div class="col-lg-6">
                    <div class="data-card">
                        <div class="data-card-header">
                            <h4 class="font-sans-serif mb-1">Clinical Cancer Research</h4>
                            <p>April 15, 2019</p>
                        </div>
                        <div class="data-card-body">
                            <p class="lead-2">Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer</p>
                            <p class="font-weight-light mb-4">Complete and timely tissue genotyping is challenging, leading to significant numbers of patients with newly diagnosed metastatic non–small cell lung cancer (mNSCLC) being undergenotyped for all eight genomic biomarkers recommended&hellip;</p>

                            <a href="https://clincancerres.aacrjournals.org/content/25/15/4691.long" class="text-red text-uppercase" target="_blank">Read more</a>
                        </div>
                    </div>
                </div>

                <div class="col-lg-6 mt-4 mt-lg-0">
                    <div class="data-card">
                        <div class="data-card-header">
                            <h4 class="font-sans-serif mb-1">Journal of Thoracic Oncology</h4>
                            <p>June 1, 2018</p>
                        </div>
                        <div class="data-card-body">
                            <p class="lead-2">A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC</p>
                            <p class="font-weight-light mb-4">Despite the significant antitumor activity of pembrolizumab in NSCLC, clinical benefit has been less frequently observed in patients whose tumors harbor EGFR mutations compared to EGFR wild-type patients. Our single-center&hellip;</p>

                            <a href="https://www.jto.org/article/S1556-0864(18)30602-6/abstract" class="text-red text-uppercase" target="_blank">Read more</a>
                        </div>
                    </div>
                </div>

            </div>            





            <div class="row mt-4">

                <div class="col-lg-6">
                    <div class="data-card">
                        <div class="data-card-header">
                            <h4 class="font-sans-serif mb-1">Clinical Lung Cancer</h4>
                            <p>April 13, 2017</p>
                        </div>
                        <div class="data-card-body">
                            <p class="lead-2">Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities</p>
                            <p class="font-weight-light mb-4">National guidelines have advocated broad molecular profiling as a part of the standard diagnostic evaluation for advanced non–small cell lung cancer (NSCLC), with the goal of identifying driver mutations for&hellip;</p>

                            <a href="https://www.clinical-lung-cancer.com/article/S1525-7304(17)30109-2/abstract" class="text-red text-uppercase" target="_blank">Read more</a>
                        </div>
                    </div>
                </div>

                <div class="col-lg-6 mt-4 mt-lg-0">
                    <div class="data-card">
                        <div class="data-card-header">
                            <h4 class="font-sans-serif mb-1">Clinical Cancer Research</h4>
                            <p>May 25, 2016</p>
                        </div>
                        <div class="data-card-body">
                            <p class="lead-2">EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis</p>
                            <p class="font-weight-light mb-4">PD-1 inhibitors are established agents in the management of non–small cell lung cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine the activity of PD-1/PD-L1 inhibitors&hellip;</p>

                            <a href="https://clincancerres.aacrjournals.org/content/22/18/4585.long" class="text-red text-uppercase" target="_blank">Read more</a>
                        </div>
                    </div>
                </div>

            </div>            



        </div>





    </main>



    <footer class="bg-black text-light">
        <div class="container py-5 py-md-6">
            <div class="row justify-content-md-between">

                <div class="col-12 col-md-6">
                    <div>                        
                        <a href="#" class="social-media-link mr-4">
                            <svg id="Icon_Twitter" xmlns="http://www.w3.org/2000/svg" width="22" height="17.875" viewBox="0 0 22 17.875">
                                <path id="Icon_Twitter-2" d="M22,2.105a9.141,9.141,0,0,1-2.245,2.342v.591A12.744,12.744,0,0,1,6.929,17.875,12.675,12.675,0,0,1,0,16.038a7.125,7.125,0,0,0,1.074.075,9.108,9.108,0,0,0,5.6-2.138,4.5,4.5,0,0,1-4.2-3.137,4.436,4.436,0,0,0,.838.086,4.513,4.513,0,0,0,1.2-.161A4.509,4.509,0,0,1,.892,6.338V6.284a4.524,4.524,0,0,0,2.041.559A4.491,4.491,0,0,1,.913,3.1,4.3,4.3,0,0,1,1.525.913a12.827,12.827,0,0,0,9.292,4.63,4.7,4.7,0,0,1-.1-1.042,4.493,4.493,0,0,1,4.5-4.5,4.669,4.669,0,0,1,3.319,1.418,9.06,9.06,0,0,0,2.847-1.1,4.475,4.475,0,0,1-1.987,2.5A8.8,8.8,0,0,0,22,2.105Z"/>
                            </svg>
                        </a>

                        <a href="#" class="social-media-link mr-4">
                            <svg id="Icon_LinkedIn" xmlns="http://www.w3.org/2000/svg" width="21.451" height="21" viewBox="0 0 21.451 21">
                                <path id="Icon_LinkedIn-2" d="M12.065,21H7.593V10.274c0-.027-.073-2.664-.073-3.131h4.4l.146,1.917A4.814,4.814,0,0,1,16.087,6.7a5.007,5.007,0,0,1,3.856,1.618,6.821,6.821,0,0,1,1.507,4.635V21H16.979V13.406c0-1.99-.886-3.132-2.43-3.132a2.454,2.454,0,0,0-1.744.669,2.745,2.745,0,0,0-.739,2.013V21ZM4.912,21H.45V7.143H4.912V21ZM2.66,4.912H2.629A2.466,2.466,0,0,1,0,2.451,2.353,2.353,0,0,1,.738.707,2.811,2.811,0,0,1,2.7,0a2.475,2.475,0,0,1,2.66,2.451A2.373,2.373,0,0,1,4.632,4.2,2.8,2.8,0,0,1,2.66,4.912Z"/>
                            </svg>
                        </a>

                        <a href="#" class="social-media-link">
                            <svg id="Icon_YouTube" xmlns="http://www.w3.org/2000/svg" width="30.102" height="21.08" viewBox="0 0 30.102 21.08">
                                <path id="a" d="M121.282,88.3a3.769,3.769,0,0,0-2.666-2.661C116.275,85,106.862,85,106.862,85s-9.415,0-11.762.629A3.774,3.774,0,0,0,92.439,88.3a42.015,42.015,0,0,0,0,14.489,3.773,3.773,0,0,0,2.661,2.661c2.349.629,11.762.629,11.762.629s9.415,0,11.759-.629a3.769,3.769,0,0,0,2.661-2.661,42.015,42.015,0,0,0,0-14.489Zm-17.43,11.759V91.031l7.827,4.514Z" transform="translate(-91.81 -85)"/>
                            </svg>
                        </a>
                    </div>
                    <div class="mt-5">
                        <strong>ClearYourView.org</strong>
                        <p class="mb-0">220 Saginaw Drive, Redwood City, CA 94063</p>
                        <p class="mb-0">&copy;2020, All Rights Reserved</p>
                    </div>

                </div>

                <div class="col-12 col-md-6 text-lg-right mt-5 mt-md-0">

                    <p>Email: Team@ClearYourView.org</p>

                    <div class="mt-5 mt-md-4">
                        <p class="mb-0"><a href="terms-of-use.html">Terms of Use</a></p>
                        <p class="mb-4"><a href="privacy-policy.html">Privacy Policy</a></p>
                        <p class="mb-0"><a href="references.html">Comprehensive Reference Guide</a></p>
                    </div>

                </div>

            </div>
        </div>
    </footer>
</body>
</html>


